Medical News: Recent Episodes
ReachMD
Guest: Neeraj Agarwal, MD, FASCO
Guest: Elena Castro, MD, PhD
Guest: Neal Shore, MD, FACS
Guest: Axel S. Merseburger, MD
While the development of advanced prostate cancers is largely influenced by androgen receptor (AR) signaling, DNA-damage response (DDR) pathways also contribute to disease progression. AR axis-targeted therapies (ARATs) have been the standard of care for first-line mCRPC. Inhibiting PARP activity is an effective strategy for targeting malignant cells with limited DNA repair capacity due to DDR gene mutations, leading to synthetic lethality. There may be a synergy between ARATs and PARP inhibitors (PARPi), as ARATs can induce HRR deficiencies and PARP inhibitors can increase the activity of ARATs through AR-dependent transcription. Recent clinical trial results have demonstrated that the combination of PARPi with ARATs is safe and effective for the first-line treatment of patients with mCRPC, with 3 combinations now FDA-approved: olaparib + abiraterone, talazoparib + enzalutamide, and niraparib + abiraterone.
This activity will provide expert contextualization of evidence from first-line mCRPC clinical trials exploring these combinations, including insights about the differentiation of both treatment and patient selection, as well as management of treatment-related toxicities. Given the differences in approvals and guidelines between the US and European context, this Ryder Cup themed Expert Panel Discussion will compare and contrast the approach in both regions, giving participants comprehensive education on …
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Madhu Grover, MBBS
Gastroparesis can be a complex disease to understand—and treat. What therapeutics are currently available? Dr. Peter Buch is joined by Dr. Mandu Grover, an Associate Professor of Medicine at the Mayo Clinic, to take a look at current treatment options.
Host: Hector O. Chapa, MD, FACOG
ACOG's Annual Clinical and Scientific Meeting will be held virtually this year, but that doesn't mean the content is any less collaborative and impactful. Listen in to hear what ReachMD's host and practicing OB-GYN, Dr. Hector Chapa, is looking forward to at this year's meeting.
Host: Linda Bernstein, Pharm.D.
Asthma remains a significant global health problem, and more than 25 million Americans suffer from it. How have the National Asthma Education and Prevention Program’s guidelines changed to help manage this chronic condition? In this episode of The Drug Report, Dr. Linda Bernstein reviews new guidelines on the management of asthma in adolescents and adults.
Published December 10, 2020
Host: Jennifer Caudle, DO
Guest: Tracey Evans, MD
Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.
In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P<0.0001).1
Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997]; P=0.0462)).2
Visit TagrissoHCP.com to learn what these data could mean for your patients.
FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring …
Host: Matt Birnholz, MD
After the American College of Surgeons and the Surgeon General's suspension of non-emergent surgeries and procedures, Dr. Matt Birnholz explains the new guidelines and their impact on patients.
Published April 2, 2020
[Read the Article]
The U.S. Preventative Services Task Force has updated the recommendations regarding colorectal cancer screening. The Task Force strongly recommends screening average risk adults age 50 to 75 for colorectal cancer, and then making individual screening decisions for adults age 76 to 85, taking into account the patient's overall health and screening history.
Colorectal cancer is the second leading cause of cancer death in the United States, and about one-third of adults in the United States have never been screened.
[Watch more videos of The JAMA Report]